EP4522106A1 - Temperaturstabile emulsionen - Google Patents
Temperaturstabile emulsionenInfo
- Publication number
- EP4522106A1 EP4522106A1 EP23717996.5A EP23717996A EP4522106A1 EP 4522106 A1 EP4522106 A1 EP 4522106A1 EP 23717996 A EP23717996 A EP 23717996A EP 4522106 A1 EP4522106 A1 EP 4522106A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- weight
- emulsion
- proportion
- total
- emulsion according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
Definitions
- cosmetic products not only serve to look beautiful and attractive, but their effect also contributes significantly to people's increased self-esteem and well-being. Accordingly, a wide variety of cosmetic products are used for daily cleansing and care of human skin.
- the two liquids are water and oil and oil droplets are finely distributed in water, then it is an oil-in-water emulsion (O/W emulsion, e.g. milk).
- O/W emulsion oil-in-water emulsion
- the basic character of an O/W emulsion is shaped by the water.
- a water-in-oil emulsion (W/O emulsion, e.g. butter) is the opposite principle, with the basic character being determined by the oil.
- acrylate-based polymers are usually incorporated into these formulations.
- Acrylate-based polymers are polymers that are obtained from homo- or copolymerization with acrylic and/or methacrylic acid. Examples of this include carbomer or acrylate copolymer.
- Emulsions with acrylates are known, among others, from DE 10148825 A1, DE 19938756 A1 and DE 29924371 U1.
- Formulations with acrylate-based polymers have a number of advantages.
- the formulations are often characterized by low stickiness.
- the formulations are well protected against the formation of flocculation and/or lumps when stored for longer periods of time, for example over 30 days at -10°C. If the temperature of the formulation is increased back to 20°C after storage for 30 days at -10°C, it is described as soft and smooth.
- the use of these acrylate-based polymers is increasingly being criticized because their biodegradability has not been fully clarified.
- the disadvantage of the state of the art is that it is hardly possible to combine low stickiness and temperature stability against flocculation or lump formation at -10 ° C over several months without using acrylate-based polymers. It is known to those skilled in the art to use short-chain diols, which leads to better temperature stability but at the same time increases the stickiness of the formula. The use of individual biopolymers or different combinations often leads to inadequate temperature stability or high stickiness.
- the invention relates to an acrylate-free cosmetic emulsion comprising a) an emulsifier system which forms a liquid-crystalline network in the emulsion, b) hydroxypropyl starch phosphate and/or distarch phosphate c) gellan gum.
- acrylate-free means that it does not contain any polymers that are obtained from homo- or copolymerization with acrylic and/or methacrylic acid.
- fatty alcohols have a C-10 to C-20 carbon chain. Accordingly, the alcohol residues of the fatty alcohol glucosides also have such a carbon chain.
- the presence of the emulsifier system causes a liquid crystalline network to form in the formulation.
- a liquid crystalline network is characterized and defined by the fact that liquid crystalline structures are formed.
- the emulsifier system must contribute to the formation of liquid crystalline structures.
- the invention also relates to the use of the emulsion of the invention to provide a cosmetic product. It is advantageous to use an oil-in-water (0/W) emulsion.
- weight percentages are given below without reference to a specific composition or specific mixture, these details always refer to the total weight of the cosmetic emulsion. If ratios of components/substances/groups of substances are disclosed below, these ratios refer to weight ratios of the components/substances/groups of substances mentioned.
- weight percentage ranges for the components of the cosmetic emulsion are given below, the disclosure of the present application also includes all individual values in increments of 0.1% by weight within these weight percentage ranges.
- the formulations “according to the invention”, “advantageous according to the invention”, “advantageous in the sense of the present invention”, etc. always refer to both the preparation according to the invention and the use according to the invention.
- normal conditions means 20°C, 1013 hPa and a relative humidity of 50%.
- skin it preferably refers to human skin.
- viscosity values refer to a measurement at 25 ° C in a 150 ml wide-mouth bottle (VWR No.: 807-001) using Rheomat R 123 from proRheo.
- the Rheomat R 123 from proRheo GmbH is a rotational viscometer, i.e. H. a measuring body rotates in the substance to be measured. The force required to rotate the measuring body in the sample at a specified speed is measured. The viscosity is calculated from this torque, the speed of the measuring body and the geometric dimensions of the measuring system used.
- the measuring body used is the measuring body no. 2 (item no. 200 0192), speed range 62.5 min-1.
- the emulsion has an emulsifier system which forms a liquid-crystalline network in the emulsion.
- the presence of such a network is accordingly a feature of the emulsion according to the invention. It is advantageously a liquid-crystalline gel network.
- the emulsifier system according to the invention advantageously comprises at least one fatty alcohol glucoside.
- the fatty alcohol glucoside is advantageously selected from the group with the INCI names Arachidyl Glucoside; 010-16 Alkyl Glucosides; 012-18 Alkyl Glucosides; 012-20 Alkyl Glucosides; Coco-glucoside; 09-11 Alkyl Glucosides; caprylyl/caprylic glucoside; caprylyl glucosides; cetearyl glucosides; Decyl Glucoside; isostearyl glucosides; Lauryl Glucoside; Myristyl Glucoside and/or Undecyl Glucoside.
- Cetearyl glucosides, caprylyl glucosides, caprylyl/capryl glucosides, lauryl glucosides and myristyl glucosides are preferred. Cetearyl glucoside is particularly preferred.
- the proportion by weight of the total fatty alcohol glucosides in the emulsion is advantageously from 0.1 to 5.0% by weight, preferably from 0.5 to 3.5% by weight, preferably from 0.6 to 2.5% by weight. % and particularly preferably from 0.9 to 2.2% by weight, based in each case on the total weight of the emulsion.
- the proportion of cetearyl glucosides, caprylyl glucosides, caprylyl/capryl glucosides, lauryl glucosides and/or myristyl glucosides is from 0.1 to 5.0% by weight, preferably from 0.5 to 3.5% by weight .-%, preferably 0.6 to 2.5% by weight and particularly preferably from 0.9 to 2.2% by weight, in each case based on the total weight of the emulsion. It is particularly advantageous if the proportion of cetearyl glucoside is from 0.1 to 5.0% by weight, preferably from 0.5 to 3.5% by weight, preferably from 0.6 to 2.5% by weight. and particularly preferably from 0.9 to 2.2% by weight, based in each case on the total weight of the emulsion.
- the emulsifier system comprises sorbitan stearate. If sorbitan stearate is included, the total proportion of sorbitan stearate is advantageously from 0.1 to 1.5% by weight, preferably 0.15 to 1.0% by weight and in particular 0.2 to 0.8% by weight. %, based on the total weight of the emulsion.
- the emulsifier system comprises disodium cetearyl sulfosuccinate. If disodium cetearyl sulfosuccinate is included, the total proportion of disodium cetearyl sulfosuccinate is advantageously from 0.01 to 0.5% by weight, preferably 0.02 to 0.2% by weight and in particular 0.04 to 0.10% by weight .-%, based on the total weight of the emulsion.
- the emulsifier system comprises glyceryl stearate. If glyceryl stearate is included, the total proportion of glyceryl stearate is advantageously from 0.1 to 1.8% by weight, preferably 0.5 to 1.5% by weight and in particular 0.7 to 1.2% by weight. %, based on the total weight of the emulsion.
- the emulsifier system advantageously additionally comprises myristyl alcohol.
- the proportion of myristyl alcohol is advantageously from 0.2 to 6.5% by weight, preferably from 0.5 to 6.0% by weight, preferably from 1.5 to 5.0% by weight, preferably from 2.5% to 4.5% by weight and particularly preferably 3.0 to 4.0% by weight, based in each case on the total weight of the emulsion.
- Liquid crystalline structures in emulsions can be visualized using light microscopy with polarized light.
- the liquid crystalline structures in the emulsion of the invention are advantageously present in a globular structure. This can be recognized by the appearance of the typical Maltese crosses in light micrographs with polarized light.
- the emulsion of the invention comprises at least hydroxypropyl starch phosphates and/or distarch phosphates.
- the total proportion of hydroxypropyl starch phosphates and/or distarch phosphates is advantageously from 0.1 to 3.0% by weight, preferably from 0.2 to 1.5% by weight and particularly preferably from 0.25 to 0.9% by weight. -%, based on the total weight of the emulsion.
- the emulsion of the invention comprises gellan gum.
- the proportion of gellan gum is advantageously from 0.01% by weight to 0.5% by weight, preferably from 0.03% by weight to 0.3% by weight and particularly preferably from 0.04 to 0.2 % by weight, based on the total weight of the emulsion.
- xanthan gum is also included. If xanthan gum is included, it is preferred if the proportion of xanthan gum is from 0.01% by weight to 0.5% by weight, preferably 0.03% by weight to 0.3% by weight and particularly preferably 0.04 to 0.2% by weight, based on the total weight of the emulsion.
- polysaccharide gums the substances known under the INCI names Guar Gum, Sclerotium Gum and/or Tara Gum are preferred.
- the proportion of cellulose in the emulsion is advantageously from 0.01 to 4% by weight, preferably from 0.3 to 2.5% by weight, preferably from 0.5 to 1.5% by weight and particularly preferably from 0.6 to 1.0% by weight, based on the total weight of the emulsion.
- Myristyl Myristate it is advantageous if the proportion of Myristyl Myristate is from 0.5 to 5.5% by weight, preferably from 1.0 to 4.5% by weight and particularly preferably from 1.4 to 3 .0% by weight, based on the total weight of the emulsion.
- Hydrogenated Coco-Glycerides it is preferred if the proportion of Hydrogenated Coco-Glycerides is from 0.1 to 3.0% by weight, preferably 0.3 to 2.0% by weight and preferably 0.5 up to 1.5% by weight, based on the total weight of the emulsion.
- Coco-Caprylate/Caprate is particularly preferred here. If an ester of a coconut fatty alcohol is contained, the proportion of these esters is advantageously from 0.2 to 4% by weight, preferably from 0.4 to 2.5% by weight and particularly preferably from 0.8 to 1.5% by weight. -%, based on the total weight of the emulsion. If coco-caprylate/caprate is included, the proportion of coco-caprylate/caprate is advantageously from 0.2 to 4% by weight, preferably from 0.4 to 2.5% by weight and particularly preferably from 0.8 to 1.5% by weight, based on the total weight of the emulsion.
- oils which are triglycerides of 3 identical fatty acids. Triisostearin is particularly preferred. If triglycerides of 3 identical fatty acids are contained, the proportion of these triglycerides is advantageously from 0.05 to 2% by weight, preferably from 0.08 to 1.0% by weight and particularly preferably from 0.1 to 0.5% by weight .-%, based on the total weight of the emulsion. If triisostearin is included, the proportion of triisostearin is advantageously from 0.05 to 2% by weight, preferably from 0.08 to 1.0% by weight and particularly preferably from 0.1 to 0.5% by weight, based on the total weight of the emulsion.
- fatty alcohols having 16 to 24 carbon atoms are contained, the total proportion of these fatty alcohols being from 0.01 to 1.5% by weight, preferably from 0.1 to 0.3% by weight , based on the total weight of the emulsion.
- cetearyl alcohol is present in a proportion of 0.01 to 1.5% by weight, preferably 0.1 to 0.3% by weight, based on the total weight of the emulsion.
- one or more fatty acids having 14 to 24 carbon atoms are contained in the emulsion, the proportion of which is advantageously from 0.2 to 5.0% by weight, preferably from 1.5% by weight. -% to 4% by weight and particularly preferably from 1.8 to 3.0% by weight, based on the total weight of the emulsion.
- the emulsion according to the invention is preferably characterized in that it contains glycerin in a proportion of 0.5% by weight to 15% by weight, preferably 3.0 to 7% by weight, based on the total weight of the emulsion.
- the emulsion contains phenoxyethanol, dehydroacetic acid, benzyl alcohol and/or ethylhexylglycerol.
- the proportion of benzyl alcohol is from 0.05% by weight to 0.5% by weight, based on the total weight of the emulsion.
- the total proportion of phenoxyethanol is from 0.1% by weight to 1.2% by weight, based on the total weight of the emulsion.
- the emulsion contains ethylhexylglycerol, it is preferred if the proportion of ethylhexylglycerol is from 0.1% by weight to 1.0% by weight, based on the total weight of the emulsion.
- embodiments of the invention are characterized in that they contain ethanol. If ethanol is contained in the emulsion, the proportion of ethanol is preferably from 0.5% by weight to 10% by weight, preferably from 1.5% by weight to 5.0% by weight, based on the total weight of the emulsion Emulsion.
- the emulsion contains one or more active ingredients selected from the group of compounds glycyrrhetinic acid, urea, arctin, folic acid, coenzyme Q10 (ubiquinone), alpha-glucosylrutin, carnitine, carnosine, caffeine, natural and / or synthetic isoflavonoids, glyceryl glucose, creatine, creatinine, taurine, tocopherol, tocopherol acetate vitamin C, vitamin C phosphate, vitamin C palmitate, niacinamide, vitamin A palmitate, panthenol, licochalcone A, rucinol, N-[(2,4-dihydroxyphenyl)thiazole 2-yl]isobutyramide, honociol and magnolol (also as a component of magnolia extracts), hyaluronic acid and/or silymarin (milk thistle extract).
- active ingredients selected from the group of compounds glycyrrhe
- emulsions advantageous according to the invention have a viscosity of 8000 mPa s to 30,000 mPa-s 24 hours after production. If viscosity is mentioned in this disclosure, all values refer to a measurement at 25 ° C in a 150 ml rolled-rim glass using Rheomat R 123 from proRheo.
- the Rheomat R 123 from proRheo GmbH is a rotational viscometer, ie a measuring body rotates in the substance to be measured. The force required to rotate the measuring body in the sample at a specified speed is measured. The viscosity is calculated from this torque, the speed of the measuring body and the geometric dimensions of the measuring system used.
- the measuring body used is the measuring body no. 2 (item no. 200 0192), speed range 62.5 min -1 . All viscosity measurements are always carried out 24 hours after the emulsion has been prepared.
- Example 1 is an example not according to the invention, which represents a common formulation with the acrylate-based polymer carbomer. After storage for 30 days at -10°C and subsequent thawing at 20°C, the formulation of Example 1 was examined. The formulation has low stickiness. In addition, after thawing there is little lump formation and is therefore uniform, smooth and soft. The formulation does not have any liquid crystalline structures.
- Example 2 is an example not according to the invention, in which the addition of polymers was omitted.
- the same storage and thawing process was used as in Example 1.
- the formulation is characterized by low stickiness, but significantly increased clumping is observed after thawing.
- Examples 3 to 7 are also reference examples not according to the invention, which tend to increase the formation of lumps after thawing.
- Various polymers are used here.
- Examples 8 to 10 are example formulations according to the invention. These have globular liquid-crystalline structures, which were detected using light microscopy with polarized light. Surprisingly, it was found that the presence of the liquid-crystalline structures in conjunction with the polymers according to the invention leads to a stabilization of the formulations with regard to the formation of lumps after thawing. Furthermore, it was surprisingly found that a low level of stickiness was found. Consequently, the disadvantages caused by the omission of acrylate-containing polymers were mitigated by the present invention.
- Example 11 is an example not according to the invention, which shows that freeze stability at -10 ° C can be achieved with the addition of diols such as butylene glycol, but there is a significant, undesirable increase in stickiness.
- the emulsion is then spread over the test area using circular movements with the entire palm of the hand (one circle per second).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Emergency Medicine (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102022204660.9A DE102022204660A1 (de) | 2022-05-12 | 2022-05-12 | Temperaturstabile Emulsionen |
| PCT/EP2023/059901 WO2023217492A1 (de) | 2022-05-12 | 2023-04-17 | Temperaturstabile emulsionen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4522106A1 true EP4522106A1 (de) | 2025-03-19 |
Family
ID=86053971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP23717996.5A Pending EP4522106A1 (de) | 2022-05-12 | 2023-04-17 | Temperaturstabile emulsionen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250268802A1 (de) |
| EP (1) | EP4522106A1 (de) |
| CN (1) | CN119384263A (de) |
| DE (1) | DE102022204660A1 (de) |
| MX (1) | MX2024013964A (de) |
| WO (1) | WO2023217492A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102024202868A1 (de) * | 2024-03-26 | 2025-10-02 | Beiersdorf Aktiengesellschaft | Kosmetische Emulsion mit Distärkephosphat und Gummis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19938756A1 (de) | 1999-08-16 | 2001-02-22 | Beiersdorf Ag | Dünnflüssige kosmetische oder dermatologische Zubereitungen vom Typ Öl-in-Wasser |
| DE29924371U1 (de) | 1999-09-15 | 2002-11-28 | Beiersdorf Ag, 20253 Hamburg | O/W-Emulsionen mit einem Gehalt an einem oder mehreren Biochinonen und einem erhöhten Gehalt an Glycerin |
| DE10148825B4 (de) | 2001-10-04 | 2004-10-07 | Beiersdorf Ag | O/W-Emulsionen mit unpolaren Wirkstoffen, deren kosmetische und/oder dermatologische Zubereitungen und deren Verwendung |
| KR102105256B1 (ko) * | 2018-12-05 | 2020-04-29 | (주) 에이텍 | 죽여추출물이 포접된 입방상 지질나노구조체를 함유하는 민감피부용 화장료 조성물 및 그 제조방법 |
| CN109430429A (zh) * | 2018-12-28 | 2019-03-08 | 上海海融食品科技股份有限公司 | 一种浓缩奶油及其制备方法 |
-
2022
- 2022-05-12 DE DE102022204660.9A patent/DE102022204660A1/de not_active Ceased
-
2023
- 2023-04-17 US US18/857,689 patent/US20250268802A1/en active Pending
- 2023-04-17 CN CN202380033996.3A patent/CN119384263A/zh active Pending
- 2023-04-17 EP EP23717996.5A patent/EP4522106A1/de active Pending
- 2023-04-17 WO PCT/EP2023/059901 patent/WO2023217492A1/de not_active Ceased
-
2024
- 2024-11-11 MX MX2024013964A patent/MX2024013964A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024013964A (es) | 2024-12-06 |
| WO2023217492A1 (de) | 2023-11-16 |
| US20250268802A1 (en) | 2025-08-28 |
| CN119384263A (zh) | 2025-01-28 |
| DE102022204660A1 (de) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3843693A1 (de) | Acrylatfreie kosmetische emulsion | |
| US12527731B2 (en) | Acrylate-free cosmetic emulsion | |
| EP3843697B1 (de) | Milde reinigungszubereitung ii | |
| EP3930665B1 (de) | Acrylat- und silikonfreie kosmetische o/w-emulsion | |
| EP4522106A1 (de) | Temperaturstabile emulsionen | |
| WO2022157055A1 (de) | Temperaturstabile, mineralölfreie w/o-emulsion | |
| WO2021037713A1 (de) | Ölersatz für kosmetische zubereitungen | |
| WO2023217480A1 (de) | Emulsion mit flüssigkristallinen strukturen | |
| CN118526422A (zh) | 身体乳 | |
| EP4021378B1 (de) | Acrylat- und silikonfreie kosmetische o/w-emulsion | |
| WO2026087103A1 (de) | Kombination aus retinol, alkylamidothiazolen und flavonoiden zur verbesserung der wirkstoffstabilisierung | |
| EP1566170A1 (de) | Hautpflegeprodukt enthaltend Ursolsäure und Ginkgo-Extrakt | |
| WO2025068245A1 (de) | Kosmetisches reinigungsprodukt mit dehydroxanthan gum | |
| WO2025081339A1 (en) | Cosmetic product comprising 4-t-butylcyclohexanol, monoglyceryl ester and an oil | |
| DE102023203936A1 (de) | Retinolhaltige kosmetische Zubereitung mit guter Hautverträglichkeit | |
| WO2022248486A1 (de) | Hydrogele mit biopolymeren | |
| EP4346745A1 (de) | Hydrogele mit biopolymeren | |
| EP4701743A1 (de) | Retinolhaltige kosmetische zubereitung mit guter stabilität, hautverträglichkeit und wirksamkeit | |
| WO2025081335A1 (en) | Cosmetic product comprising 4-t-butylcyclohexanol, polyglyceryl ester and an oil | |
| WO2024223515A1 (de) | Retinolhaltige kosmetische zubereitung mit guter stabilität und hautverträglichkeit | |
| EP4701742A1 (de) | Retinolhaltige kosmetische zubereitung mit guter hautverträglichkeit | |
| CN115040437A (zh) | O/w乳剂形式的化妆品组合物 | |
| Ribeiro | Development and Characterization of Novel Vehicles for Topical Drug Delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20241212 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20251031 |